Rauch 2009.

Methods	Single centre, placebo‐controlled RCT. Parallel trial.
Participants	Risedronate: 13 Placebo: 13 Mean age (SD): 11.9 (4) years placebo, 11.7 (3.6) years risedronate 15 male, 11 female OI types I
Interventions	Risedronate (or placebo) 15 mg  once per week if < 40 kg 30 mg once per week if > 40 kg
Outcomes	Every 3 months for bone pain, grip force, blood and urine tests and anthropometric measurements Every 12 months for bone age, radiographs of spine, BMD by DXA Baseline and 24 months for radiographs of long bones (or whenever a fracture sustained) Bone biopsy at 24 months
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients were randomised in equal number to receive either risedronate or placebo.  Both risedronate and placebo pills were provided by the manufacturer."
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Risedronate: 2 withdrew (lack of effect, refused to take pills) Placebo: 1 withdrew (lack of effect).
Selective reporting (reporting bias)	High risk	Bone age stated as measured but not reported and grip strength was reported as not significant. Authors have been contacted for data.
Other bias	Low risk	None.